Silexion Therapeutics Stock (NASDAQ:SLXN)
Previous Close
$2.47
52W Range
$2.35 - $63.45
50D Avg
$3.45
200D Avg
$10.84
Market Cap
$1.32M
Avg Vol (3M)
$476.19K
Beta
-0.07
Div Yield
-
SLXN Company Profile
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.